Compare Amplify Transformational Data Sharing ETF (BLOK) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amplify Transformational Data Sharing ETF vs Neurocrine Biosciences Inc — how do they compare? Amplify Transformational Data Sharing ETF trades at $58.96, while Neurocrine Biosciences Inc trades at $161.94 (market cap $16.76B). The key difference: Neurocrine Biosciences Inc is trading nearer its 52-week high, Amplify Transformational Data Sharing ETF nearer its low. Which is the better fit depends on your goals.
| BLOK | NBIX | |
|---|---|---|
52-Week High | $74.10 | $185.50 |
52-Week Low | $47.36 | $123.10 |
Market Cap | — | $16.76B |
Sector | — | Health |
Enterprise Value | — | $16.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BLOK trades at $59.89 with minimal daily movement (+0.4%). Technical indicators show a bearish trend with all 13 moving averages signaling sell, while oscillators remain neutral. The stock faces resistance at $60 and support at $59. Recent news highlights the ETF's diversified blockchain economy exposure and inclusion of SpaceX shares following its historic IPO.
The outlook remains cautious due to strong bearish technical signals and sector volatility. Investment opportunity lies in diversified blockchain economy exposure, but risks include market sentiment shifts and competitive ETF landscape. Wall Street sentiment appears mixed with technical weakness offset by strategic positioning in growing sectors.
Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.
The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amplify Transformational Data Sharing ETF
The fund is an actively managed ETF that seeks to provide total return by investing at least 80% of its net assets in the equity securities of companies actively involved in the development and utilization of "transformational data sharing technologies". It may invest in non-US equity securities, including depositary receipts.
Read more on BLOK →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
